stockrowQuest Diagnostics Incorporated
DGX Healthcare Diagnostics & Research
Quest Diagnostics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $11.0 billion, up 11.8% from fiscal 2024.
- Revenue
- +9.98%
- EPS
- +29.4%
- Free cash flow
- +6.21%
- Total debt
- −2.20%
Quarter to September 2026, against a year earlier
Follow DGX
Alert me
Quest Diagnostics Incorporated (DGX) EPS (diluted)
Quest Diagnostics Incorporated's EPS (diluted) for fiscal 2025 was $8.75, up 13.8% from $7.69 in fiscal 2024. Over the twelve months to 30 September 2026 it was $10.04. Over the past ten years it has ranged from $4.51 (fiscal 2016) to $15.55 (fiscal 2021); the current reading is higher than 82% of that period. Quest Diagnostics Incorporated ranks 6th of 49 Diagnostics & Research companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $8.75 | 13.78% |
| FY2024 | $7.69 | 2.67% |
| FY2023 | $7.49 | (6.02%) |
| FY2022 | $7.97 | (48.75%) |
| FY2021 | $15.55 | 48.52% |
| FY2020 | $10.47 | 66.72% |
| FY2019 | $6.28 | 18.71% |
| FY2018 | $5.29 | (3.82%) |
| FY2017 | $5.50 | 21.95% |
| FY2016 | $4.51 | (7.39%) |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $2.78 | (2.11%) |
| Jun 2026 | $2.84 | 26.79% |
| Mar 2026 | $2.24 | 2.75% |
| Dec 2025 | $2.18 | 0.93% |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| MTD Mettler-Toledo International, Inc. compare | $44.43 |
| MEDP Medpace Holdings, Inc. compare | $18.04 |
| LH Labcorp Holdings Inc. compare | $12.19 |
| DGX Quest Diagnostics Incorporated | $10.04 |
| IQV IQVIA Holdings Inc. compare | $8.24 |
| ILMN Illumina, Inc. compare | $5.81 |
| WAT Waters Corporation compare | $2.33 |
| RVTY Revvity Inc. compare | $2.26 |
| GH Guardant Health, Inc. compare | −$3.68 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on DGX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement